Table 2.
Patient characteristics for ovarian cancer patients (N = 118)
| Characteristic | N | % |
|---|---|---|
| Median age, years |
58 |
|
| Age range, years |
33–82 |
|
| FIGO stage |
|
|
| 1 |
16 |
14 |
| 2 |
17 |
14 |
| 3 |
71 |
60 |
| 4 |
14 |
12 |
| ECOG performance |
|
|
| 0 |
70 |
59 |
| 1 |
41 |
35 |
| 2+ |
6 |
5 |
| Missing |
1 |
1 |
| Baseline neutrophils > 3.9 |
|
|
| Yes |
98 |
83 |
| No |
20 |
17 |
| Optimal debulking |
|
|
| No |
36 |
31 |
| Yes |
80 |
68 |
| Missing |
2 |
<2 |
| Ascites at surgery |
|
|
| No |
32 |
27 |
| yes |
79 |
67 |
| Missing |
7 |
6 |
| Normalized CA125 |
|
|
| No |
16 |
14 |
| yes |
96 |
81 |
| Missing |
6 |
5 |
| Chemotherapy regimens |
|
|
| Carbo + Tax |
73 |
62 |
| Carbo monotherapy |
33 |
28 |
| Carbo + other | 12 | 10 |
Abbreviations: FIGO International Federation of Gynaecology and Obstetrics, ECOG Eastern Cooperative Oncology Group; CA125 Cancer Antigen 125; Carbo Carboplatin; Tax Taxol (Paclitaxel).